Bank of New York Mellon Corp Invests $628,000 in CeriBell (NASDAQ:CBLL)

Bank of New York Mellon Corp acquired a new stake in CeriBell (NASDAQ:CBLL - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 24,274 shares of the company's stock, valued at approximately $628,000. Bank of New York Mellon Corp owned approximately 0.07% of CeriBell as of its most recent SEC filing.

Separately, Rhumbline Advisers acquired a new position in CeriBell in the fourth quarter valued at about $320,000.

Analyst Ratings Changes

Several equities analysts have recently weighed in on CBLL shares. Canaccord Genuity Group reiterated a "buy" rating and set a $33.00 price objective on shares of CeriBell in a report on Wednesday, February 26th. TD Cowen raised their target price on shares of CeriBell from $31.00 to $36.00 and gave the stock a "buy" rating in a report on Monday, December 9th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $32.60.

CeriBell Stock Performance

CeriBell stock traded down $0.37 during midday trading on Friday, reaching $19.46. The stock had a trading volume of 136,057 shares, compared to its average volume of 243,690. CeriBell has a 1-year low of $18.69 and a 1-year high of $32.75. The company's fifty day moving average is $22.33.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The firm had revenue of $18.53 million during the quarter, compared to the consensus estimate of $17.55 million. As a group, equities research analysts predict that CeriBell will post -2.46 EPS for the current year.

Remove Ads

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.